ABSTRACT
This study was aimed at investigating the sampling strategies for 2 types of figures: 3-D cubes and human faces. The research was focused on: (a) from where the sampling process started; (b) in what order the figures' features were sampled. The study consisted of 2 experiments: (a) sampling strategies for 3-D cubes; (b) sampling strategies for human faces. The results showed that: (a), for 3-D cubes, the first sampling was mostly located at the outline parts, rarely at the center part; while for human faces, the first sampling was mostly located at the hair and outline parts, rarely at the mouth or cheek parts, in most cases, the first sampling-position had no significant effects on cognitive performance and that (b), the sampling order, both for 3-D cubes and for human faces, was determined by the degree of difference among the sampled-features.
Subject(s)
Cognition/physiology , Discrimination Learning/physiology , Pattern Recognition, Visual/physiology , Psychomotor Performance/physiology , Cues , Face , Female , Humans , Male , Sample SizeABSTRACT
OBJECTIVE: To evaluate the targeting ability and cytotoxicity of domain III of pseudomonas exotoxin encapsulated in anti-CD19-immunoliposomes to lymphoma cells in vitro and in vivo. METHODS: Binding ability of anti-CD19 immunoliposomes to B lymphoma cells was detected by binding assay. MTT assay was used to detect the cytotoxicity of free domain III and domain III encapsulated in anti-CD19-immunoliposomes against B lymphoma cells. An in vivo therapeutic study of domain III formulated in immunoliposomes on human B lymphoma was detected in a murine model. RESULTS: The cytotoxicity of free domain III disappeared when domain I and II were deleted. When domain III was encapsulated into anti-CD19-immunoliposomes, the cytotoxicity of immunoliposomes against tumor cells were significantly increased. Treatment, using this formulation, of mice inoculated with B lymphoma could enhance the survival time. CONCLUSION: Anti-CD19-immunoliposomes, as drug carriers, can specifically recognize B lymphoma cells and deliver non-toxic domain III into the tumor cells. This formulation of domain III might be an effective anti-tumor agent.
